The X chromosome moves from passive to key driver of cancer biology
In the architecture of human biology, the X chromosome has long been treated as background—present, necessary, but rarely implicated as a protagonist in disease. A multinational research team has now revealed that in a specific subtype of the most common adult blood cancer, women carrying two particular gene mutations face mortality rates more than four times higher than men with identical mutations—not because of hormones or lifestyle, but because of the chromosomal geometry unique to the female body. The discovery, emerging from institutions in Barcelona, New York, and Vancouver, does more than explain a disparity; it opens a therapeutic door that was invisible until the right question was asked.
- Women with simultaneous SPEN and NOTCH2 mutations in diffuse large B-cell lymphoma are dying at more than four times the rate of men with the same genetic profile—a disparity hidden in plain sight across nearly five thousand patients.
- The culprit is not estrogen or lifestyle but the X chromosome itself: when SPEN fails, the silencing of a second X chromosome destabilizes, awakening TLR7, a gene that helps tumors survive and spread—a mechanism biologically impossible in men.
- Researchers confirmed the effect persisted even after removing ovaries from animal models, dismantling the long-held assumption that sex differences in cancer are primarily hormonal and forcing a reckoning with chromosomal biology as an independent driver.
- IRAK kinase inhibitors—already in clinical development for other conditions—can block the TLR7 pathway driving this female-specific tumor growth, and in laboratory models they proved markedly more effective against tumors from women than from men.
- Combining IRAK inhibitors with standard chemotherapy amplified results and may allow lower chemo doses, a critical advantage for elderly patients who represent the disease's most frequent victims and are least able to tolerate aggressive treatment.
A multinational research team led by Professor Ari Melnick, working across institutions in Barcelona, New York, and Vancouver, has identified a lethal subtype of diffuse large B-cell lymphoma—the most common blood cancer in adults—that kills women at more than four times the rate it kills men. Analyzing data from nearly five thousand patients across fourteen independent studies, the researchers found the disparity concentrated in women whose tumors carried simultaneous mutations in two genes, SPEN and NOTCH2. The same genetic damage, dramatically different outcomes. The question was why.
The answer resided not in hormones but in chromosomal architecture. Women carry two X chromosomes, one of which is normally silenced through a process partly governed by SPEN. When SPEN is mutated alongside NOTCH2, that silencing becomes unstable—dormant genes begin to reactivate, including TLR7, which when overactive helps tumor cells survive and proliferate. Men, with only a single X chromosome, are structurally incapable of experiencing this mechanism. To confirm that female hormones were not responsible, the team removed the ovaries of laboratory animals. The effect persisted. The vulnerability was chromosomal, not endocrine—a distinction that challenges decades of assumptions about why cancer behaves differently across sexes.
The discovery carries immediate clinical weight. The TLR7 pathway can be blocked by IRAK kinase inhibitors, a drug class already in clinical trials for other diseases, shortening the typical distance between laboratory finding and patient benefit. In experimental models, these inhibitors proved significantly more effective against tumors from women than from men, and combining them with standard chemotherapy amplified results while potentially allowing lower doses—a meaningful advantage for the elderly patients who develop this cancer most frequently.
The research also reframes the disease's origins, suggesting the lymphoma may arise from a cell type linked to aging and infection exposure rather than the immune response centers previously implicated—possibly explaining why many patients may have carried an undetected precursor condition for years. Professor Melnick described the work as a paradigm shift: the X chromosome, long treated as a passive element, emerges as a key driver of cancer biology in women, and biological sex moves from a demographic footnote to an essential variable in how oncology trials are designed and how treatments are matched to patients.
A team of international researchers has identified a lethal subtype of diffuse large B-cell lymphoma—the most common blood cancer in adults—that kills women at more than four times the rate it kills men. The discovery, led by Professor Ari Melnick at the Josep Carreras Leukemia Research Institute in Barcelona, alongside Dr. Wendy Béguelin at New York University and Dr. Leandro Venturutti at the University of British Columbia, upends decades of assumptions about how this disease behaves across sexes.
The researchers analyzed data from nearly five thousand patients across fourteen independent studies and found the disparity in a specific subset: women whose tumors carried simultaneous mutations in two genes, SPEN and NOTCH2, faced mortality risk more than four times higher than men carrying the identical mutations. The finding forced a fundamental question: why would the same genetic damage produce such different outcomes based on sex?
The answer lay in the X chromosome itself. Women carry two copies of the X chromosome; one is normally silenced through a process partly controlled by the SPEN gene. But when SPEN is mutated alongside NOTCH2, that silencing becomes unstable. Genes that should remain dormant begin to wake up—including TLR7, which, when overactive, helps tumor cells survive and proliferate. Men, possessing only a single X chromosome, cannot experience this mechanism at all. Dr. Benedikt Pelzer, the study's lead author, described the moment the team grasped the mechanism: they realized the key was not in hormones or lifestyle, but in the chromosome itself.
The researchers tested whether female hormones played a role by removing the ovaries of laboratory animals. The effect persisted. This was the crucial finding: the vulnerability was chromosomal, not hormonal—a distinction that challenges the conventional wisdom that sex differences in cancer arise from estrogen, progesterone, or other endocrine factors. As Dr. Venturutti noted, differences between men and women in cancer have long been attributed to lifestyle or hormones, but this work demonstrates that molecular biology can be fundamentally distinct at the chromosomal level, and such differences can remain invisible unless specifically sought.
The discovery has immediate therapeutic implications. The TLR7 pathway driving tumor growth in affected women can be blocked by IRAK kinase inhibitors—a class of drugs already in clinical development for other diseases. In laboratory experiments and animal models, these inhibitors proved significantly more effective at eliminating tumor cells from women than from men. When tested on a tumor model derived directly from a patient with this form of lymphoma, the drug produced a marked reduction in growth. Combining the IRAK inhibitor with standard chemotherapy amplified the effect, potentially allowing lower chemotherapy doses—a meaningful advantage for elderly patients, who develop this cancer most frequently.
Dr. Béguelin emphasized the urgency of translation: IRAK inhibitors are already in clinical trials, meaning the path from laboratory discovery to therapeutic option for patients is shorter than typical in cancer research. The work also reframes the cancer's origin. Researchers had long believed this lymphoma subtype arose in the active immune response centers of lymph nodes. New evidence suggests it may instead originate from a cell type that accumulates with age and infection exposure, closely linked to autoimmune disease—a finding that could explain why the disease strikes older patients more frequently, many of whom may have harbored an undetected precursor condition for years.
Professor Melnick called the work a paradigm shift: the X chromosome moves from a passive element to a key driver of cancer biology in women, and the identification of a therapeutic target provides solid ground for incorporating biological sex as a standard variable in oncology trial design. Diffuse large B-cell lymphoma affects hundreds of thousands of people worldwide each year. Though many respond to standard treatment, roughly one-third do not achieve lasting remission, leaving the disease potentially fatal. This research suggests that for a significant subset of women, a more precise therapeutic path now exists.
Citas Notables
When SPEN is altered alongside NOTCH2, the inactivation of the X chromosome becomes unstable, allowing supposedly dormant genes like TLR7 to activate and promote tumor cell survival.— Dr. Benedikt Pelzer, lead author
This work redefines the role of the X chromosome from a passive element to a key factor in cancer biology in women, and represents a genuine paradigm shift arguing for biological sex as a standard variable in oncology trial design.— Professor Ari Melnick, Josep Carreras Leukemia Research Institute
La Conversación del Hearth Otra perspectiva de la historia
Why did it take so long to notice that women were dying at different rates from this specific cancer?
Because researchers weren't looking at sex as a biological variable—they were treating it as a demographic category. When you analyze five thousand patients together without separating by sex, a four-fold difference in one subgroup can disappear into the noise.
But the mutations are the same in men and women. What makes the X chromosome the culprit?
Women have two X chromosomes, and one gets turned off to balance gene expression. That silencing is fragile when SPEN is broken. In men, there's only one X, so there's nothing to silence. The same mutation produces completely different biology depending on how many X chromosomes you have.
The researchers tested this by removing ovaries in animals. Why was that the decisive experiment?
Because it ruled out hormones. If estrogen or progesterone were driving the difference, removing the ovaries would eliminate it. The effect stayed. That proved the vulnerability lives in the chromosome itself, not in the endocrine system.
So IRAK inhibitors already exist. Why aren't they being used right now?
They're in clinical development for other diseases. The research shows they work in the lab and in animal models, but you can't give a drug to patients without clinical trials. What this study does is give oncologists a reason to prioritize testing these drugs in this specific population.
Does this change how we should think about sex differences in cancer more broadly?
It should. For decades, we've blamed lifestyle or hormones for most sex differences in cancer outcomes. This work shows that at the molecular level, being male or female can create fundamentally different disease biology—even with identical mutations. If we're not looking for it, we'll keep missing it.
What happens to the women with this subtype right now, before these drugs reach patients?
They get standard chemotherapy, which works for some but fails for others. The hope is that within a few years, they'll have an option that targets their specific biology—and possibly at lower doses, which matters when you're older and your body is more fragile.